ONCO-BCG is a form of Bacillus Calmette–Guérin (BCG), a live but weakened strain of Mycobacterium bovis. It is used as an intravesical immunotherapy for treating early-stage bladder cancer, particularly non-muscle invasive bladder cancer. ONCO-BCG is administered directly into the bladder through a catheter and is one of the most effective treatments for preventing recurrence and progression of bladder tumors.

Mechanism of Action:
ONCO-BCG works by stimulating the body’s immune system to attack bladder cancer cells. When introduced into the bladder, the BCG bacteria interact with the bladder lining, triggering an immune response that brings white blood cells and other immune factors to the area. This immune activation helps destroy cancer cells and reduces the risk of the tumor growing or coming back.

Uses:
ONCO-BCG is mainly used for:

• Treatment of superficial or non-muscle invasive bladder cancer

• Prevention of tumor recurrence after surgical removal of bladder tumors

• Reducing the risk of progression to more invasive stages of bladder cancer

  Adverse Effects:
  ONCO-BCG can cause both local and systemic side effects. Common ones include:

  • Increased urinary frequency or urgency

  • Burning sensation during urination

  • Mild fever, fatigue, or flu-like symptoms

  • Blood in the urine